Patents by Inventor Richard D. Levere

Richard D. Levere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6110472
    Abstract: The invention teaches compositions useful for treating conditions characterized by excess exfoliation or hyperkeratinization, such as dandruff. These compositions include vitamin B12 in an amount sufficient to alleviate exfoliation. Dandruff is one condition which may be treated using the formulations.
    Type: Grant
    Filed: August 4, 1994
    Date of Patent: August 29, 2000
    Assignee: Hemogen Inc.
    Inventors: Richard D. Levere, Nadar G. Abraham, Michal L. Schwartzman, Michael W. Dunn
  • Patent number: 5783201
    Abstract: Vitamin B12 is used to stimulate heme oxygenase production. In turn, levels of the molecules 12(R)-HETE and 12(R)-DIHETE, which are arachidonic acid derivatives, are reduced. Various topical formulations containing vitamin B12, but no other vitamins, are described.
    Type: Grant
    Filed: April 3, 1997
    Date of Patent: July 21, 1998
    Assignee: Hemogen, Inc.
    Inventors: Richard D. Levere, Nadar G. Abraham, Michal L. Schwartzman, Michael W. Dunn
  • Patent number: 5674505
    Abstract: Vitamin B12 is used to stimulate heme oxygenase production. In turn, levels of the molecules 12(R)-HETE and 12(R)-DIHETE, which are arachidonic acid derivatives, are reduced. Various topical formulations containing vitamin B12, but no other vitamins, are described.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: October 7, 1997
    Assignee: Hemogen, Inc.
    Inventors: Richard D. Levere, Nadar G. Abraham, Michal L. Schwartzman, Michael W. Dunn
  • Patent number: 5217997
    Abstract: A method for treating a high vascular resistance disorder in a mammal by administering to a mammalian organism in need of such treatment a sufficient amount of L-arginine or pharmaceutically acceptable salt thereof to treat a high vascular resistance disorder. The L-arginine is typically administered in the range of about 1 mg to 1500 mg per day. High vascular resistance disorders include hypertension, primary or secondary vasospasm, angina pectoris, cerebral ischemia and preeclampsia. Also disclosed is a method for preventing or treating bronchial asthma in a mammal by administering to a mammalian organism in need of such prevention or treatment a sufficient amount of L-arginine to prevent or treat bronchial asthma.
    Type: Grant
    Filed: April 24, 1992
    Date of Patent: June 8, 1993
    Inventors: Richard D. Levere, Nader G. Abraham, Michel L. Schwartzman, Pavel Martasek
  • Patent number: 5102670
    Abstract: The invention relates to a method for treating or preventing ocular swelling and corneal-conjunctival inflammation. This is accomplished by administering to the eye of a subject, either before or after exposure to an ocular swelling stimulus, an amount of a heme oxygenase inducing agent sufficient to increase levels of heme oxygenase in the eye and thereby to reduce or to regulate the amount of 12(R) hydroxyeicosatetraenoic and 12(R) DiHETE acids present. Particularly preferred agents include stannous compounds, such as SnCl.sub.2, other metals, heme derivatives and Vitamin B12. These compounds may be administered in various forms.
    Type: Grant
    Filed: September 14, 1990
    Date of Patent: April 7, 1992
    Inventors: Nader G. Abraham, Michal L. Schwartzman, Michael W. Dunn, Richard D. Levere